Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV)

41 filings reported holding VERV - Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2024.
Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) has 17 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 4.39M shares of 89.6M outstanding shares and own 4.9% of the company stock.
Largest 10 shareholders include JPMORGAN CHASE & CO (1.49M shares), CITADEL ADVISORS LLC (1.18M shares), MORGAN STANLEY (886K shares), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (487K shares), Bank of New York Mellon Corp (225K shares), Legal & General Group Plc (53.9K shares), DEUTSCHE BANK AG\ (31.5K shares), NEW YORK STATE COMMON RETIREMENT FUND (22.1K shares), Voya Investment Management LLC (20.7K shares), and Royal Bank of Canada (17.7K shares).
This table shows the top 17 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.